Dose Modification of Imatinib by Monitoring the Level of BCR-ABL Transcript in Chronic Myelogenous Leukemia

この論文にアクセスする

この論文をさがす

著者

    • KATO CHIAKI
    • Division of Hematology, National Hospital Organization Nagoya Medical Center
    • HARIGAE HIDEO
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • TOMIYA YASUO
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • YAMADA MINAMI
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • ISHIZAWA KENICHI
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • KAMEOKA JUNICHI
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • MIYAMURA KOICHI
    • Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital
    • SASAKI TAKESHI
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine

抄録

Chronic myelogenous leukemia (CML) is a hematological malignancy that is characterized by the chromosome anomaly, t(9;22)(q34;q11). By this chromosomal translocation, a novel activated tyrosine kinase, BCR-ABL chimeric protein, is generated, and the protein is causative of the disease. Recently, Imatinib mesylate targeting to a BCR-ABL chimeric protein has been developed, and shown to achieve complete remission at a high rate. Patients are currently required to receive a fixed dose, 400 mg daily; however, it is possible that some of patients can maintain their remission with reduced doses of imatinib. In this study, we determined levels of BCR-ABL transcript in CML patients by real-time quantitative polymerase chain reaction analysis, and explored the possibility of individualization of therapeutic doses of imatinib. Thirty-five CML patients, including 17 newly diagnosed patients, 16 patients pre-treated with interferon-alpha, and 2 relapsed patients after allogeneic transplantation, were treated with imatinib. Complete cytogenetic response was achieved in 31 (89%) patients. Major molecular response (MMR) was achieved in 21 (60%). Complete molecular response (CMR) was achieved in 7 (20%). Imatinib was discontinued in 2 patients, one patient with MMR due to noncompliance and other patient sustaining CMR, but both patients relapsed 7 and 13 months later, respectively. The doses of imatinib were reduced in 7 patients due to its side effects, but 4 out of the 7 patients have sustained MMR, and 2 of them have sustained CMR for more than 23 months. These results indicate that some patients are able to maintain MMR with low-dose imatinib.

収録刊行物

  • THE TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE  

    THE TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE 210(4), 355-363, 2006-12-01 

    Tohoku University Medical Press

参考文献:  28件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  2件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10018809985
  • NII書誌ID(NCID)
    AA00863920
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    00408727
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ